Drugs /

elimusertib

Back to Drugs List

Overview

NCI Definition [1]:
An orally available ataxia telangiectasia and Rad3-related (ATR)-specific kinase inhibitor, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor BAY1895344 selectively binds to and inhibits the activity of ATR, which prevents ATR-mediated signaling. This inhibits DNA damage checkpoint activation, disrupts DNA damage repair and induces apoptosis in ATR-overexpressing tumor cells. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and cell survival.

Clinical Trials

View Clinical Trials for elimusertib

Elimusertib has been investigated in 8 clinical trials, of which 7 are open and 1 is closed. Of the trials investigating elimusertib, 8 are phase 1 (7 open).

ARID1A Loss, ARID1A Mutation, and ATM Loss are the most frequent biomarker inclusion criteria for elimusertib clinical trials.

Malignant solid tumor, breast carcinoma, and colorectal carcinoma are the most common diseases being investigated in elimusertib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Elimusertib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Elimusertib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating elimusertib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bay1895344, bay-1895344, bay 1895344, atr inhibitor bay1895344, atr kinase inhibitor bay1895344
Drug Categories [2]:
Serine/threonine kinase inhibitors
Drug Target(s) [2]:
ATR
NCIT ID [1]:
C146807

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.